嗜中性白血球低下症市场规模、份额和成长分析（按治疗类型、风险因子、药物类别和地区划分）－2026-2033年产业预测

预计到 2024 年，全球嗜中性白血球低下症市场规模将达到 125.5 亿美元，到 2025 年将达到 132.4 亿美元，到 2033 年将达到 203.3 亿美元，在预测期（2026-2033 年）内复合成长率为 5.5%。

发烧性嗜中性白血球低下症市场受多种关键因素驱动，包括全球癌症发生率上升、化疗使用增加以及长效粒细胞集落刺激因子（G-CSF）疗法的进展。此外，生物相似药的广泛应用提高了治疗可近性，而对支持治疗指南的认识不断提高，也促进了早期疗育，从而降低了住院率。然而，挑战依然存在，例如生物相似药的高成本限制了中低收入社区的用药。缺乏认知和诊断延迟可能导致併发症和住院治疗。同时，长期使用G-CSF引发了人们对副作用和抗菌素抗药性的担忧。此外，某些市场对生物相似药核准的监管不确定性阻碍了患者获得价格合理的治疗，从而限制了整体市场成长。

嗜中性白血球低下症市场驱动因素

全球癌症发生率的上升显着增加了嗜中性白血球低下症的风险，尤其是在接受化疗的患者身上。癌症病例的激增推动了发烧性嗜嗜中性白血球低下症症市场的扩张，这主要得益于人们对该疾病的认识不断提高，以及对早期诊断和支持性治疗（例如粒细胞集落刺激因子[G-CSF]）的需求不断增长。此外，肿瘤治疗路径中早期疗育疗法的显着增加也促进了市场成长。随着医疗保健相关人员将有效管理嗜中性白血球低下症列为优先事项，市场格局也不断演变以满足这些不断变化的需求。

限制嗜中性白血球低下症市场的因素

全球发烧性嗜嗜中性白血球低下症市场面临许多限制因素，尤其是在中低收入国家，患者难以承担生物製药治疗的经济负担。保险覆盖不足和高昂的自付费用加剧了这项挑战，导致患者无法及时接受治疗。这些经济负担构成了严重的就医障碍，造成治疗差异，并对患者预后产生负面影响。因此，这些地区嗜中性白血球低下症症的整体预后受到医疗系统资金筹措限制的影响，凸显了增加资金和资源以改善患者照护和获得必要治疗的必要性。

嗜中性白血球低下症市场趋势

全球发烧性嗜嗜中性白血球低下症市场正经历显着的变革时期，这主要得益于生物相似药在癌症支持治疗领域日益广泛的应用。诸如Filgrastim和Pegfilgrastim等产品正迅速发展，显着降低了治疗成本，从而提高了患者（尤其是在发展中地区）获得治疗的机会。这一趋势正在推动全球癌症治疗的公平性，确保患者无论经济状况如何都能获得所需的治疗。此外，生物相似药的引入促进了供应商之间的良性竞争，推动了创新并改善了治疗选择。因此，嗜中性白血球低下症的治疗格局正在快速演变，这反映了全球范围内实现全面患者照护的积极方向。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

嗜中性白血球低下症市场规模（按治疗类型和复合年增长率划分）（2026-2033 年）

• 预防性治疗
• 治疗

全球嗜中性白血球低下症市场规模（按风险因子和复合年增长率划分）（2026-2033 年）

• 化疗引起的嗜中性白血球低下症
• 移植相关性嗜中性白血球低下症
• 遗传性疾病

嗜中性白血球低下症市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 抗生素
• 颗粒细胞增生因子
• 抗真菌药物
• 抗病毒药物

嗜中性白血球低下症市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Amgen Inc.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（USA）
• Biocon Biologics Ltd（India）
• Coherus BioSciences, Inc.（USA）
• Kyowa Kirin Co., Ltd.（Japan）
• Spectrum Pharmaceuticals, Inc.（USA）
• Hanmi Pharmaceutical Co., Ltd.（South Korea）
• BeyondSpring Inc.（USA）
• G1 Therapeutics, Inc.（USA）
• Partner Therapeutics, Inc.（USA）
• Cellerant Therapeutics, Inc.（USA）
• Fresenius Kabi（Germany）
• Intas Pharmaceuticals Ltd.（India）
• Gedeon Richter Plc.（Hungary）
• Aurobindo Pharma Limited（India）
• Amneal Pharmaceuticals, Inc.（USA）
• Merck & Co., Inc.（USA）

结论与建议

Global Febrile Neutropenia Market size was valued at USD 12.55 Billion in 2024 and is poised to grow from USD 13.24 Billion in 2025 to USD 20.33 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The febrile neutropenia market is driven by several key factors, including the rising incidence of cancer worldwide, increased chemotherapy utilization, and advancements in long-acting G-CSF therapies. Additionally, the growing availability of biosimilars has enhanced treatment access, while awareness of supportive care guidelines promotes early intervention, consequently reducing hospitalization rates. However, challenges persist, such as the high costs associated with biosimilar medications, which limit accessibility in lower and middle-income regions. Low awareness and late diagnoses lead to complications that necessitate hospitalization, while the chronic use of G-CSFs raises concerns over side effects and antibiotic resistance. Furthermore, regulatory uncertainties regarding biosimilar approvals in certain markets hinder the accessibility of affordable treatments, posing constraints to overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Febrile Neutropenia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Febrile Neutropenia Market Segments Analysis

Global Febrile Neutropenia Market is segmented by Treatment Type, Risk Factors, Drug Class and region. Based on Treatment Type, the market is segmented into Prophylactic Treatment and Therapeutic Treatment. Based on Risk Factors, the market is segmented into Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia and Genetic Disorders. Based on Drug Class, the market is segmented into Antibiotics, Granulocyte Colony-Stimulating Factors, Antifungals and Antivirals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Febrile Neutropenia Market

The rising incidence of cancer globally has significantly heightened the risk of febrile neutropenia, especially in patients undergoing chemotherapy. This surge in cancer cases has contributed to the expansion of the febrile neutropenia market, driven by a growing awareness of the condition and an increasing demand for early diagnosis and supportive treatments like G-CSFs. Additionally, there is a notable shift towards earlier intervention therapies within oncology treatment pathways, which further supports market growth. As healthcare stakeholders prioritize effective management of febrile neutropenia, the overall market landscape continues to evolve in response to these changing needs.

Restraints in the Global Febrile Neutropenia Market

The global febrile neutropenia market faces significant constraints, particularly in low and middle-income countries, where patients struggle with the financial implications of biologic therapies. The challenge is exacerbated by inadequate insurance coverage and high out-of-pocket expenses, which can deter individuals from seeking timely treatment. This economic strain creates substantial barriers to access and leads to treatment gaps that adversely affect patient outcomes. Consequently, the overall prognosis for febrile neutropenia in these regions is influenced by the limitations of funding within healthcare systems, highlighting the need for improved financial support and resources to enhance patient care and access to necessary therapies.

Market Trends of the Global Febrile Neutropenia Market

The Global Febrile Neutropenia market is witnessing a significant shift driven by the increasing adoption of biosimilars in supportive cancer care. Products like filgrastim and pegfilgrastim are gaining momentum, providing essential cost-saving benefits that enhance treatment accessibility, particularly in developing regions. This trend fosters equitable cancer care on a global scale, ensuring that patients receive necessary therapies regardless of their financial background. Additionally, the introduction of biosimilars stimulates healthy competition among providers, driving innovation and improving treatment options. As a result, the febrile neutropenia landscape is evolving rapidly, reflecting a positive trajectory towards comprehensive patient care worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Febrile Neutropenia Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Prophylactic Treatment
• Therapeutic Treatment

Global Febrile Neutropenia Market Size by Risk Factors & CAGR (2026-2033)

• Market Overview
• Chemotherapy-Induced Neutropenia
• Transplant-Related Neutropenia
• Genetic Disorders

Global Febrile Neutropenia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibiotics
• Granulocyte Colony-Stimulating Factors
• Antifungals
• Antivirals

Global Febrile Neutropenia Market Size & CAGR (2026-2033)

• North America (Treatment Type, Risk Factors, Drug Class)
  • US
  • Canada
• Europe (Treatment Type, Risk Factors, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Risk Factors, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Risk Factors, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Risk Factors, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeyondSpring Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• G1 Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Partner Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc. (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations